Insights

The success of complex and advanced therapeutic clinical trials depends heavily on a capable and adequately trained investigative workforce. One key yet often underdeveloped component of this workforce is the research-naïve principal investigator (PI)—a clinician who possesses the medical expertise required to oversee a study but lacks substantial experience in clinical trial leadership as they enter their first such experience.

Turnover in clinical operations is often discussed as an unfortunate reality of a demanding industry. Long hours, aggressive timelines, and increasing complexity are cited as unavoidable contributors. But after more than two decades leading clinical teams across sponsor and contract research organization environments, the author of this column has come to see turnover differently.

Artificial intelligence (AI) has fundamentally reshaped the clinical data industry. We routinely harness AI to generate deeper insights from complex trial data, accelerate detection of risk, and enhance oversight. Yet across the broader enterprise, many organizations have not embedded AI deeply enough into their internal workflows to unlock its full value.

For many early-career clinical researchers, trial design can feel rigid. A primary endpoint is selected, the study is powered around it, and success is determined by that single measure. But patients do not experience treatment effects through one outcome. They experience a combination of efficacy, side effects, symptoms, and quality of life. Reducing this to a single outcome can risk missing the bigger picture.

The need for diversity in clinical trials and the challenges of identifying patients who are unknown to the healthcare system complicate trial enrollment and add financial stress that may hinder the success of a study. A targeted, engineered approach to patient enrollment and diversity, using a financially calculable strategy, can ameliorate these challenges.